When to Restart Hiprex After Treating Active UTI
Restart methenamine hippurate (Hiprex) immediately after completing antibiotic therapy for the active UTI, once the infection has been eradicated. 1
Key Principle: Eradication First, Then Prophylaxis
The FDA label for Hiprex explicitly states that "this drug should only be used after eradication of the infection by other appropriate antimicrobial agents" 1. This means:
- Complete the full course of antibiotics for the active UTI (typically 3-7 days depending on the agent and whether treating cystitis vs pyelonephritis)
- Do not overlap methenamine hippurate with acute UTI treatment antibiotics
- Start Hiprex the day after finishing antibiotics—there is no waiting period required once the acute infection is treated
Clinical Rationale
Methenamine hippurate works through a fundamentally different mechanism than antibiotics. It is hydrolyzed to formaldehyde in acidic urine, providing continuous antibacterial activity 1. This prophylactic effect begins within 30 minutes of ingestion and maintains continuous antibacterial activity when dosed at 1 gram twice daily 1.
The drug is indicated specifically for "prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary" 1. It is not intended to treat active infections—that's why the acute infection must be cleared first.
Dosing After Restart
- Standard dose: 1 gram twice daily 2, 1
- Duration: Continue for at least 6 months based on recent evidence 3
- No urine acidifiers needed: Despite historical recommendations, vitamin C and other acidifiers do not enhance methenamine's effectiveness and are unnecessary 2
Important Caveat: The Rebound Effect
Recent high-quality evidence reveals a critical pitfall: discontinuing methenamine hippurate after 6 months may increase UTI risk 3. In a 2025 triple-blind RCT of 281 older women, methenamine reduced antibiotic-treated UTIs by 25% during the 6-month treatment period (IRR 0.75, p=0.049). However, during the 6-month follow-up after stopping treatment, the methenamine group experienced a 70% higher incidence of UTIs compared to placebo (IRR 1.7, p<0.001) 3.
Clinical implication: When initiating methenamine hippurate, counsel patients that this is likely a long-term or indefinite prophylactic strategy, not a short-term intervention. Abrupt discontinuation may trigger rebound UTIs.
Supporting Guideline Evidence
Both major 2024-2025 guidelines support this approach:
- The 2025 AUA/CUA/SUFU guideline states clinicians "may offer methenamine hippurate for prophylaxis for women with rUTIs," noting it provides comparable protection to antibiotics 2
- The 2024 EAU guideline gives a strong recommendation to "use methenamine hippurate to reduce recurrent UTI episodes in women without abnormalities of the urinary tract" 4
The evidence base has strengthened considerably, with methenamine demonstrating non-inferiority to daily antibiotic prophylaxis (nitrofurantoin, cephalexin, or trimethoprim) with an absolute difference of only 0.49 UTI episodes per person-year 2.
Practical Algorithm
- Diagnose active UTI with urine culture 4
- Treat with appropriate antibiotics (3-7 days depending on presentation)
- Start Hiprex 1g twice daily the day after completing antibiotics
- Continue indefinitely or for extended periods (≥6 months minimum)
- If discontinuation is necessary, taper gradually or monitor closely for rebound infections rather than stopping abruptly
This approach maximizes the prophylactic benefit while avoiding the documented rebound phenomenon associated with discontinuation 3.